ReviewPediatric nephrology (Berlin, Germany)2021
Renal tumors in tuberous sclerosis complex.
Review in Pediatric nephrology (Berlin, Germany), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 35 citations in OpenAlex.
- Features and management of kidney manifestations of tuberous sclerosis complex: a real-world study in a Brazilian patient cohort.BMC nephrology · 2026Observational
- Original investigation: evolution of long-term cardiac tumours in patients with tuberous sclerosis.Orphanet journal of rare diseases · 2026Article
- Tuberous sclerosis complex.Nature reviews. Disease primers · 2026Review
- Dual-Level Ureteral Obstruction in Children: A Systematic Review Highlighting Diagnostic Challenges and Optimal Surgical Strategy.Children (Basel, Switzerland) · 2026Review
- Case Report: Rapid progression to end-stage renal disease within 3 years in tuberous sclerosis complex challenging conventional risk stratification.Frontiers in medicine · 2026Article
- Genetic Testing and Counselling for Hereditary Renal Carcinoma: What Do Clinicians Need to Know?European urology open science · 2025Review
- Kidneys in Children with Tuberous Sclerosis Complex-An Up-to-Date Review.Journal of clinical medicine · 2025Review
- Blood Biomarkers to Identify Renal Angiomyolipomas in People With Tuberous Sclerosis Complex.Neurology. Genetics · 2025Article
- Rare genetic interstitial lung diseases: a pictorial essay.European respiratory review : an official journal of the European Respiratory Society · 2024Review
- Circulating biomarkers of kidney angiomyolipoma and cysts in tuberous sclerosis complex patients.iScience · 2024Article
- Giant cell angiofibroma of gingiva in tuberous sclerosis complex: a case report and literature review.Diagnostic pathology · 2024Review
- Hereditary Renal Cancer Syndromes.Medical sciences (Basel, Switzerland) · 2024Review
- Tuberous Sclerosis Complex and the kidneys: what nephrologists need to know.Jornal brasileiro de nefrologia · 2024Review
- Cystic kidney disease in tuberous sclerosis complex: current knowledge and unresolved questions.Pediatric nephrology (Berlin, Germany) · 2023Article
- Review
- Review
- Tuberous sclerosis complex for the pulmonologist.European respiratory review : an official journal of the European Respiratory Society · 2021Article
- The Molecular Characteristics of Non-Clear Cell Renal Cell Carcinoma: What's the Story Morning Glory?International journal of molecular sciences · 2021Review
- Early Vascular Aging in Children With Tuberous Sclerosis Complex.Frontiers in pediatrics · 2021Article
- An Adolescent with Tuberous Sclerosis and Hypocalcemia and a Renal Mass.Indian journal of nephrologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tuberous sclerosis complex (TSC) is a multisystem hereditary disorder characterized by the growth of benign tumors (hamartomas) in multiple organs, including the kidneys. Renal angiomyolipomas (AML) are a major diagnostic feature of TSC and are present in the majority of patients by adulthood. However, AML are usually asymptomatic during childhood when neurological and developmental manifestations are the main source of morbidity. Kidney manifestations of TSC have historically been the main cause of morbidity and mortality of adults with TSC. The recognition that the complications of TSC are caused by dysregulation of the mammalian target of rapamycin (mTOR) pathway has led to an enormous progress in the management of patients with TSC in the last two decades, the establishment of diagnostic guidelines, and trials which have shown the therapeutic benefit of mTOR inhibitors. Kidney surveillance of children with TSC now provides the opportunity for timely interventions to reduce the impact of TSC in adulthood. In this review, we discuss the current management of kidney tumors associated with TSC, including the diagnosis, surveillance, and treatment options for these lesions. We also present outcome data from international registries demonstrating the effectiveness of the current management strategies. With clear management guidelines and efficient treatment of kidney tumors, we envisage that the long-term outcomes of patients with TSC will further improve in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.